Gilead stock reversed higher on smaller losses early Friday as analysts noted encouraging indicators for its newly approved ...

People living with HIV who smoke are currently more likely to die from lung cancer than from HIV-related causes. Two cancer ...

Total product sales -- $7.3 billion in fiscal Q3 2025, up 4% sequentially from Q2 2025, with growth driven by the HIV ...

Gilead is actively looking for late-stage and de-risked assets for potential deals across various therapeutic spaces, ...

Zimbabwe steps in to assist Botswana with a vital shipment of anti-retroviral drugs, combining a donation and a loan to ...

Dzidzai is one of 25 Community Adolescent Treatment Supporters (CATS) trained by the National Aids Council (NAC) and the ...

Explore Gilead Sciences' Q3 2025 earnings: strong HIV portfolio growth, Yeztugo's rapid launch, and raised guidance.

Gilead has chosen a partner for lenacapavir in the race to develop new low-frequency treatments for HIV. | Gilead has chosen ...

Gilead Sciences said on Thursday its HIV drug sales rose 4% to $5.3 billion in the third quarter including $39 million for ...

More than 230 people became infected with HIV in Indiana, worsened by delayed action from former Gov. Mike Pence. Experts and ...

Patrick and Charles Boyd bought more than $90 million of the illicit drugs and sold them to unwitting customers in South ...

Gilead Sciences said on Thursday its HIV drug sales rose 4% to $5.3 billion in the third quarter including $39 million for ...